EL.En. S.p.A. (LON:0RH2)

London flag London · Delayed Price · Currency is GBP · Price in EUR
13.71
+0.04 (0.33%)
At close: May 12, 2026
Market Cap970.57M +64.9%
Revenue (ttm)515.44M +4.4%
Net Income37.87M -15.9%
EPS0.46 -15.9%
Shares Outn/a
PE Ratio25.63
Forward PE18.62
Dividend0.19 (1.35%)
Ex-Dividend DateMay 19, 2025
Volume467
Average Volume2,291
Open13.73
Previous Close13.66
Day's Range13.71 - 13.73
52-Week Range9.59 - 14.50
Beta1.10
RSI56.19
Earnings DateMay 15, 2026

About EL.En.

EL.En. S.p.A. engages in the production, research and development, distribution, and sale of laser systems in Italy, Rest of Europe, and internationally. The company offers laser systems for the medical sector and the industrial sector. It also develops, manufactures, and markets products, including solid-state laser, semiconductor laser, active fiber laser, dye lasers, and CO2 laser, as well as radio frequency, microwaves, frequency conversion systems, and high-intensity electromagnetic fields. In addition, the company is involved in medical r... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 1981
Employees 1,379
Stock Exchange London Stock Exchange
Ticker Symbol 0RH2

Financial Performance

In 2025, EL.En.'s revenue was 590.85 million, an increase of 4.42% compared to the previous year's 565.85 million. Earnings were 43.42 million, a decrease of -15.88%.

Financial numbers in EUR Financial Statements

News

EL.En. Earnings Call Transcript: Q4 2025

FY2025 saw 4.4% revenue growth and strong medical sector performance, but net profit declined due to FX losses, higher provisions, and one-time items. Guidance for 2026 is cautious, targeting 5% growth amid geopolitical and supply chain risks.

2 months ago - Transcripts

EL.En. Earnings Call Transcript: Q3 2025

Strong Q3 driven by medical sector growth and high-margin products, with consolidated revenue up 3.9% and gross margin improving. Industrial segment faced delays and competition, but cash position strengthened by asset sales. Confident in meeting 2024 guidance.

6 months ago - Transcripts

EL.En. Earnings Call Transcript: Q2 2025

Revenue grew 5.1% to €285M in H1 2025, led by medical sector gains, but EBIT and net income declined due to weaker industrial performance, FX losses, and absence of prior year one-offs. Strong order backlog supports 2025 guidance, with risks from tariffs and market softness.

8 months ago - Transcripts

EL.En. Earnings Call Transcript: Q1 2025

Q1 2025 delivered 8.8% revenue growth and improved margins, with strong performance in both medical and industrial sectors. Guidance for 2025 is raised, expecting to surpass 2024 in both revenue and EBIT, though global trade and tariff risks remain.

1 year ago - Transcripts